Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate

Bone

Volumn 46, Issue 4, 2010, Pages 929-934

  Eastell, Richard ^a   Chen, Peiqi ^b   Saag, Kenneth G ^c   Burshell, Alan L ^d   Wong, Mayme ^b   Warner, Margaret R ^e   Krege, John H ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Lilly USA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Oschner Clinic Foundation   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Alendronate; Glucocorticoid induced osteoporosis; Osteocalcin; Procollagen type I N terminal propeptide (PINP); Teriparatide

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; ARTICLE; BLOOD ANALYSIS; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; TERIPARATIDE; TREATMENT OUTCOME;

EID: 77950537281     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.12.021     Document Type: Article

References (46)

1. Adler R.A., Curtis J., Weinstein R.S., Saag K.G. Glucocorticoid-induced osteoporosis. Osteoporosis 2008, 1135-1166. Elsevier-Academic Press, Burlington, MA. R. Marcus, D. Feldman, D.A. Nelson, C.J. Rosen (Eds.).
2. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy.
3. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 2007, 18:1319-1328.
4. van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003, 48:3224-3229.
5. Canalis E., Bilezikian J.P., Angeli A., Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004, 34:593-598.
6. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 1998, 102:274-282.
7. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
8. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., Roux J.P., Portero N.R., Meunier P.J. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 2001, 16:97-103.
9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001, 44:1496-1503. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
10. van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif. Tissue. Int. 2006, 79:129-137.
11. Sambrook P.N. Anabolic therapy in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2007, 357:2084-2086.
12. McClung M.R., San M.J., Miller P.D., Civitelli R., Bandeira F., Omizo M., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 2005, 165:1762-1768.
13. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 2005, 20:1244-1253.
14. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone Miner. Res. 2006, 21:366-373.
15. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 2006, 22:61-66.
16. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 1998, 102:1627-1633.
17. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2007, 357:2028-2039.
18. Eastell R., Reid D.M., Compston J., Cooper C., Fogelman I., Francis R.M., et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. 1998, 244:271-292.
19. Ton F.N., Gunawardene S.C., Lee H., Neer R.M. Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 2005, 20:464-470.
20. Pearce G., Tabensky A., Delmas P.D., Baker H.W.G., Seeman E. Corticosteriod-induced bone loss in men. J. Clin. Endocrinol. Metab. 1998, 83:801-806.
21. Reid I.R., Chapman G.E., Fraser T.R., Davies A.D., Surus A.S., Meyer J., et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J. Clin. Endocrinol. Metab. 1986, 62:379-383.
22. Kotowicz M.A., Hall S., Hunder G.G., Cedel S.L., Mann K.G., Riggs B.L. Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum. 1990, 33:1487-1492.
23. Prummel M.F., Wiersinga W.M., Lips P., Sanders G.T., Sauerwein H.P. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J. Clin. Endocrinol. Metab. 1991, 72:382-386.
24. Clowes J.A., Peel N., Eastell R. Glucocorticoid-induced osteoporosis. Curr. Opin. Rheumatol. 2001, 13:326-332.
25. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 1998, 339:292-299.
26. Adachi J.D., Saag K.G., Delmas P.D., Liberman U.A., Emkey R.D., Seeman E., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001, 44:202-211.
27. Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 2000, 11(Suppl 6):S30-S44.
28. Naylor K.E., Iqbal P., Fledelius C., Fraser R.B., Eastell R. The effect of pregnancy on bone density and bone turnover. J. Bone Miner. Res. 2000, 15:129-137.
29. Walsh J.S., Henry Y.M., Fatayerji D., Eastell R. Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study. Osteoporos. Int. 2009, 20:355-362.
30. Fatayerji D., Eastell R. Age-related changes in bone turnover in men. J. Bone Miner. Res. 1999, 14:1203-1210.
31. Glover S.J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42:623-630.
32. Glover S.J., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., Boonen S., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J. Bone Miner. Res. 2009, 24:389-397.
33. Dalle Carbonare L., Bertoldo F., Valenti M.T., Zenari S., Zanatta M., Sella S., et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005, 36:645-652.
34. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 2001, 16:925-931.
35. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
36. Saag K.G., Zanchetta J.R., Devogelaer J.P., Adler R.A., See K., Dalsky G.P., et al. Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results. J. Bone Miner. Res. 2008, 23(Suppl 1):S49.
37. Chavassieux P.M., Arlot M.E., Roux J.P., Portero N., Daifotis A., Yates A.J., et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J. Bone Miner. Res. 2000, 15:754-762.
38. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
39. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 2003, 18:1932-1941.
40. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
41. Ma Y.L., Zeng Q., Donley D.W., Ste-Marie L.G., Gallagher J.C., Dalsky G.P., et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2006, 21:855-864.
42. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 2001, 16:1846-1853.
43. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos. Int. 2003, 14:77-81.
44. Morrison N., Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J. Bone Miner. Res. 1993, 8:969-975.
45. Leclerc N., Noh T., Khokhar A., Smith E., Frenkel B. Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer. Arthritis Rheum. 2005, 52:929-939.
46. Chavassieux P., Pastoureau P., Chapuy M.C., Delmas P.D., Meunier P.J. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos. Int. 1993, 3:97-102.